Document:

Amendment No. 2 to Collaboration Agreement

 Exhibit 10.3 
  
 AMENDMENT NO. 2 TO 
 COLLABORATION AGREEMENT 
  
 THIS AMENDMENT NO. 2
to Collaboration Agreement (this “Amendment No. 2”), effective as of August 16, 2004 (the “Second Amendment Date”), is entered into by and between Genencor International, Inc., a Delaware corporation having its
principal place of business at 925 Page Mill Road, Palo Alto, CA 94304-1013 (“GCOR”), and Seattle Genetics, Inc., a Delaware corporation having its principal place of business at 21823 30th Drive S.E. Bothell, WA 98021 (“SGI”). 
  
 RECITALS 
  
 WHEREAS, GCOR and SGI entered into a Collaboration Agreement dated as of January 4, 2002, as amended by Amendment No. 1 thereto dated as of July
28, 2003 (collectively, the “Agreement”). 
  
 WHEREAS, After consultation with SGI, GCOR has requested that SGI [***] to GCOR. 
  
 NOW THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the parties amend the Agreement and otherwise
agree as follows (with all capitalized terms used but not defined herein having the meanings set forth in the Agreement): 
  
 1. Second Work Plan. The parties hereby agree that the Second Work Plan attached hereto as Exhibit A shall be in effect from the date hereof
until expiration of the Term on January 4, 2006, and shall supersede and replace any other Work Plans previously attached to the Agreement. 
  
 2. Acknowledgement and Waiver. The Parties acknowledge and agree that, notwithstanding anything to the contrary contained in the Agreement, with
respect to all New Prodrugs (as defined below) the following terms shall apply. “New Prodrugs” means any prodrugs which are SGI Prodrug Inventions other than (a) [***] and (b) [***]. “SGI Prodrug Inventions” shall
be amended to mean the following: “Information and Inventions: (i) made prior to or during the Term [***]; and (ii) that relate to [***] or [***], or are otherwise conceived of and/or developed by [***] pursuant to the Collaboration.”

  

	 	(a)	SGI represents that as of the Second Amendment Date it has not done, nor had done on its behalf, [***]. 

  

	 	(b)	Except as may arise from breach of SGI’s representation in (a) above, [***] shall be [***] for all Third-Party royalties, milestones, fees and other obligations to third
parties with respect to New Prodrugs on account of [***]. GCOR shall indemnify SGI, its Affiliates and their respective 

  

 Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to
the confidentiality request. Omissions are designated as ***. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 
  

 - 1 - 

 directors, officers, employees and agents, and defend and save each of them harmless, from and against
any and all Losses arising from or occurring as a result of or in connection with GCOR’s use or incorporation of New Prodrugs into [***]. 
  

	 	(c)	Except as expressly set forth herein, SGI makes no representations, warranties or covenants whatsoever, either express or implied, with respect to New Prodrugs, including without
limitation: 

  

	 	(i)	as to merchantability or fitness for a particular purpose; 

  

	 	(ii)	that use or incorporation of any New Prodrugs into products [***] will not infringe any intellectual property or other rights of any third party; or 

  

	 	(iii)	as imposing any obligation on SGI to bring or prosecute actions or proceedings against third parties for infringement or to defend any action or proceedings with respect to New
Prodrugs. 

  
 3. Miscellaneous. 

 
 3.1 Continuing Effect. This Amendment No. 2 shall be effective for
all purposes as of the Second Amendment Date. Except as otherwise expressly modified by this Amendment No. 2, the Agreement shall remain in full force and effect in accordance with its terms. 
  
 3.2 Governing Laws. This Amendment No. 2 shall be governed by,
interpreted and construed in accordance with the laws of the State of Delaware, without regard to conflicts of law principles. 
  
 3.3 Counterparts. This Amendment No. 2 may be executed in counterparts, each of which shall be deemed to be an original and together shall be
deemed to be one and the same document. 
  
 (Signature page
follows) 
  

 ***
Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 - 2 - 

 IN WITNESS WHEREOF, the parties have caused this Amendment No. 2 to be executed by their respective duly
authorized officers as of the Second Amendment Date. 
  

			
	SEATTLE GENETICS, INC.
		
	By:	 	 /s/ Clay B. Siegall

	 	 	(Signature)
	Name:	 	Clay B. Siegall, Ph.D.
	Title:	 	President and Chief Executive Officer
	
	GENENCOR INTERNATIONAL, INC.
		
	By:	 	 /s/ Mark A. Goldsmith

	 	 	(Signature)
	Name:	 	Mark A. Goldsmith, MD, Ph.D.
	Title:	 	Senior Vice President, Health Care

  

 - 3 -Amendment No. 3 to License Agreement

 Exhibit 10.4 
  
 AMENDMENT NO. 3 TO 
 LICENSE AGREEMENT 
  
 THIS AMENDMENT NO. 3 to
License Agreement No. 651-01.LIC (“AMENDMENT NO. 3”), effective as of August 17, 2004 (the “THIRD AMENDMENT DATE”), is entered into by and between Arizona Science & Technology Enterprises d/b/a Arizona Technology Enterprises,
an Arizona limited liability company having its principal place of business at 699 S. Mill Avenue, Tempe, AZ 85281 (“AzTE”), acting on behalf of and for THE ARIZONA BOARD OF REGENTS and ARIZONA STATE UNIVERSITY, of Tempe, Arizona
(“ASU”) and SEATTLE GENETICS, INC., a corporation organized under the laws of Delaware having its principal place of business located at 21823 30th Drive S.E., Bothell, WA 98021 (“LICENSEE”). 
  
 RECITALS 
  
 WHEREAS, ASU and SGI entered into License Agreement No. 651-01.LIC dated as of February 3, 2000, as subsequently amended on February 18, 2000 and March 14, 2002 (collectively, the “LICENSE AGREEMENT”); 
  
 WHEREAS, the parties now wish to amend the LICENSE AGREEMENT on the
terms set forth herein; 
  
 NOW THEREFORE, in consideration
of the mutual covenants set forth below, the parties amend the LICENSE AGREEMENT and otherwise agree as follows (with all capitalized terms used but not defined herein having the meanings set forth in the LICENSE AGREEMENT): 
  
 AGREEMENT 
  
 1. ASU acknowledges and agrees that ASU’s [***]. ASU acknowledges and agrees that the LICENSEE [***] with respect to
products utilizing or incorporating [***]. 
  
 2. Section 2.5 of
the LICENSE AGREEMENT is amended and restated to read in its entirety as follows: 
  
 “2.5 This Agreement and grant of license hereunder are subject to the terms and conditions contained throughout this Agreement.” 
  
 3. Section 5.1.1 of the LICENSE AGREEMENT is amended and restated to read in its entirety as follows: 
  
 “The LICENSEE shall pay to ASU the following fees: 
  
 (a) Within [***] of the THIRD AMENDMENT DATE, a [***] of
[***] ($[***]). 
  
 (b) Beginning in [***], an
[***] until expiration of the 
  

 Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as ***. A complete version of this
exhibit has been filed separately with the Securities and Exchange Commission. 

 last to expire of the VALID CLAIMS within ASU’s PATENT RIGHTS. For purposes of illustration, the
[***] payment schedule shall be as follows: 
  
 [***] 
  
 3. The provisions of Sections 5.2-5.14, 9.1,
9.2, 9.4 and 9.5 of the LICENSE AGREEMENT shall apply only to [***], and not [***]. Articles 8 and 14 and Sections 5.1.3 and 5.1.4 of the LICENSE AGREEMENT are deleted in their entireties. 
  
 4. This AMENDMENT NO. 3 is effective for all purposes as of the THIRD
AMENDMENT DATE. Except as otherwise expressly modified by this AMENDMENT NO. 3, the LICENSE AGREEMENT remains in full force and effect in accordance with its terms. 
  
 5. This AMENDMENT NO. 3 may be executed in counterparts, each of which shall be deemed to be an original and together shall
be deemed to be one and the same document. 
  
 6. [***] (as
defined in the LICENSE AGREEMENT) pursuant to a [***]. [***] represents and warrants that it has all necessary power and authority to [***] in entering into this AMENDMENT NO. 3, which shall be binding and enforceable in all respects with regard to
[***]. 
  
 [Signature page follows] 
  

 *** Certain information on this
page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 -2- 

 IN WITNESS WHEREOF, the parties have caused this AMENDMENT NO. 3 to be executed by their respective duly
authorized officers as of the THIRD AMENDMENT DATE. 
  

			
	SEATTLE GENETICS, INC.
		
	By:	 	 /s/ Clay B. Siegall

	 	 	(Signature)
	Name:	 	Clay B. Siegall, Ph.D.
	Title:	 	President and Chief Executive Officer
	
	ARIZONA SCIENCE & TECHNOLOGY ENTERPRISES
		
	By:	 	 /s/ Peter Slate

	 	 	(Signature)
	Name:	 	Peter Slate
	Title:	 	Chief Executive OfficerForm of Promissory Note dated July 12, 2005

 Exhibit 10.14 
  
 PROMISSORY NOTE 
  

			
	$85,000	 	As of July 12, 2005

  
 Shine Media Acquisition Corp. (the
“Maker”) promises to pay to the order of              (the “Payee”) the principal sum of Eighty-Five Thousand Dollars and No Cents ($85,000.00) in lawful money of
the United States of America, together with interest on the unpaid principal balance of this Note, on the terms and conditions described below. 
  
 1. Principal. The principal balance of this Note shall be repayable on the earlier of (i) July 12, 2006 or (ii) the date on which Maker consummates
an initial public offering of its securities. 
  
 2.
Interest. Interest shall accrue at the rate of 4% annually (non-compounded) on the unpaid principal balance of this Note. 
  
 3. Application of Payments. All payments shall be applied first to payment in full of any costs incurred in the collection of any sum due under
this Note, including (without limitation) reasonable attorneys’ fees, then to the payment of any accrued interest and finally to the reduction of the unpaid principal balance of this Note. 
  
 4. Events of Default. The following shall constitute Events of
Default: 
  
 (a) Failure to Make Required Payments.
Failure by Maker to pay the principal of or accrued interest on this Note within five (5) business days following the date when due. 
  
 (b) Voluntary Bankruptcy, Etc. The commencement by Maker of a voluntary case under the Federal Bankruptcy Code, as now constituted or hereafter
amended, or any other applicable federal or state bankruptcy, insolvency, reorganization, rehabilitation or other similar law, or the consent by it to the appointment of or taking possession by a receiver, liquidator, assignee, trustee, custodian,
sequestrator (or other similar official) of Maker or for any substantial part of its property, or the making by it of any assignment for the benefit of creditors, or the failure of Maker generally to pay its debts as such debts become due, or the
taking of corporate action by Maker in furtherance of any of the foregoing. 
  
 (c) Involuntary Bankruptcy, Etc. The entry of a decree or order for relief by a court having jurisdiction in the premises in respect of maker in an involuntary case under the Federal Bankruptcy Code, as now or
hereafter constituted, or any other applicable federal or state bankruptcy, insolvency or other similar law, or appointing a receiver, liquidator, assignee, custodian, trustee, sequestrator (or similar official) of Maker or for any substantial part
of its property, or ordering the winding-up or liquidation of the affairs of Maker, and the continuance of any such decree or order unstayed and in effect for a period of 60 consecutive days. 

 5. Remedies. 
  
 (a) Upon the occurrence of an Event of Default specified in Section 4(a), Payee may, by written notice to Maker, declare
this Note to be due and payable, whereupon the principal amount of this Note, and all other amounts payable thereunder, shall become immediately due and payable without presentment, demand, protest or other notice of any kind, all of which are
hereby expressly waived, anything contained herein or in the documents evidencing the same to the contrary notwithstanding. 
  
 (b) Upon the occurrence of an Event of Default specified in Sections 4(b) and 4(c), the unpaid principal balance of, and all other sums payable with
regard to, this Note shall automatically and immediately become due and payable, in all cases without any action on the part of Payee. 
  
 6. Waivers. Maker and all endorsers and guarantors of, and sureties for, this Note waive presentment for payment, demand, notice of dishonor,
protest, and notice of protest with regard to the Note, all errors, defects and imperfections in any proceedings instituted by Payee under the terms of this Note, and all benefits that might accrue to Maker by virtue of any present or future laws
exempting any property, real or personal, or any part of the proceeds arising from any sale of any such property, from attachment, levy or sale under execution, or providing for any stay of execution, exemption from civil process, or extension of
time for payment; and Maker agrees that any real estate that may be levied upon pursuant to a judgment obtained by virtue hereof, on any writ of execution issued hereon, may be sold upon any such writ in whole or in part in any order desired by
Payee. 
  
 7. Unconditional Liability. Maker hereby waives
all notices in connection with the delivery, acceptance, performance, default, or enforcement of the payment of this Note, and agrees that its liability shall be unconditional, without regard to the liability of any other party, and shall not be
affected in any manner by any indulgence, extension of time, renewal, waiver or modification granted or consented to by Payee, and consents to any and all extensions of time, renewals, waivers, or modifications that may be granted by Payee with
respect to the payment or other provisions of this Note, and agrees that additional makers, endorsers, guarantors, or sureties may become parties hereto without notice to them or affecting their liability hereunder. 
  
 8. Notices. Any notice called for hereunder shall be deemed properly
given if (i) sent by certified mail, return receipt requested, (ii) personally delivered, (iii) dispatched by any form of private or governmental express mail or delivery service providing receipted delivery, (iv) sent by telefacsimile or (v) sent
by e-mail, to the following addresses or to such other address as either party may designate by notice in accordance with this Section: 
  
 If to Maker: 
  
 Shine Media Acquisition Corp. 
 Rockefeller Center 
 1230 Avenue of the Americas, 7th Floor 
 New York, New York 10020 
 Attn: David Y. Chen, Chief Executive Officer

  

 2 

 If to Payee: 
  
  

 [To his address on file at
Shine Media Acquisition Corp.’s office] 
  
 Notice shall be deemed
given on the earlier of (i) actual receipt by the receiving party, (ii) the date shown on a telefacsimile transmission confirmation, (iii) the date on which an e-mail transmission was received by the receiving party’s on-line access provider
(iv) the date reflected on a signed delivery receipt, or (vi) two (2) Business Days following tender of delivery or dispatch by express mail or delivery service. 
  
 9. Construction. This Note shall be construed and enforced in accordance with the domestic, internal law, but not the
law of conflict of laws, of the State of New York. 
  
 10.
Severability. Any provision contained in this Note which is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the
remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. 
  
 IN WITNESS WHEREOF, Maker, intending to be legally bound hereby, has caused this Note to be duly executed by its Chief
Executive Officer the day and year first above written. 
  

			
	SHINE MEDIA ACQUISITION CORP.
		
	By:	 	  

	Name:	 	David Y. Chen
	Title:	 	Chief Executive Officer

  

 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00088-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00088-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00088-of-00352.parquet"}]]